Abstracts tagged "Adalimumab"

Abstract Number: 619 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Analysis of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients with Active Psoriatic Arthritis
Peter Nash¹, Laura C Coates², Roy Fleischmann³, Kim Papp⁴, Juan J. Gomez-Reino⁵, Keith S Kanik⁶, Cunshan Wang⁶, Joseph Wu⁶, Thijs Hendrikx⁷ and William C Ports⁶, ¹Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ⁴Probity Medical Research and K. Papp Clinical Research Inc, Waterloo, ON, Canada, ⁵Fundacion Ramon Dominguez, Hospital Clinico Universitario, Santiago de Compostela, Spain, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for treatment of psoriatic arthritis (PsA). We examined tofacitinib efficacy in patients (pts) with active…
Abstract Number: 2280 • 2017 ACR/ARHP Annual Meeting
Effectiveness of Switching to Adalimumab As the Second- and Third-Line Biological Drug in Patients with Juvenile Idiopathic Arthritis
Ekaterina Alexeeva¹, Tatiana Dvoryakovskaya², Victor Gladkikh^3,4, Andrei Moskalev^4,5, Rina Denisova¹, Ksenia Isaeva¹, Olga Lomakina¹, Margarita Soloshenko¹ and Anna Karaseva¹, ¹Reumatology department, Federal State Autonomous Institution"National Scientific and Practical Center of Children's Health"Of the Ministry of Health of the Russian Federation, Moscow, Russian Federation, ²Pediatrics, The Federal State Autonomous Educational Institution of Higher Education The First Moscow State Medical University named after I.M. Sechenov Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russian Federation, ³Department of Biostatistics, EOL Labs ltd, Novosibirsk, Rwanda, ⁴Laboratory of Computational Physics, Institute of Computational Mathematics and Mathematical Geophysics SB RAS, Novosibirsk, Russian Federation, ⁵Department of Biostatistics, EOL Labs ltd, Novosibirsk, Russian Federation
Background/Purpose: The range of biological drugs currently used in JIA therapy includes not only anti-TNF but also other varieties. However, despite the high effectiveness and…
Abstract Number: 961 • 2017 ACR/ARHP Annual Meeting
Adalimumab Reduces CXCR4 Expression during Inflammatory Arthritis and in Fibroblast-like Synoviocytes and Osteoclasts Under Chronic TNF Exposure
Bohdan P. Harvey¹, Li Li¹, Mark Konrad¹, Heather Knight¹, Susan Westmoreland², Melanie Ruzek¹ and Zehra Kaymakcalan¹, ¹AbbVie Bioresearch Center, Worcester, MA, ²AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: The CXCL12/CXCR4 chemokine axis has been implicated in the pathogenesis of RA. The expression of this chemokine and receptor has been shown to be…
Abstract Number: 2283 • 2017 ACR/ARHP Annual Meeting
Adalimumab Therapy in Juvenile Idiopathic Arthritis: Addition of Lidocaine for Prevention of Injection Site Pain or Not? That Is the Question. a Comparison Study
Barbara Ostrov¹, Brandt Groh², Lisabeth V. Scalzi³, C. April Bingham², Natalya Gaffney², Meredith Buckley², Lisa Robbins² and Rosanne Ayala⁴, ¹Pediatrics, Penn State Hershey Medical Center, Hershey, PA, ²Pediatrics, Penn State College of Medicine, Hershey, PA, ³Penn State Hershey Medical Center, Hershey, PA, ⁴Penn State College of Medicine, Hershey, PA
Background/Purpose: Up to 37% of patients prescribed adalimumab (AD) report significant injection-site pain (Registered Prescribing Information, 2016). For AD to be a stable pre-filled product,…
Abstract Number: 1038 • 2017 ACR/ARHP Annual Meeting
Impact of Patient Support Program Utilization on Patient Activation Measure Scores Among Patients with Rheumatoid Arthritis
Filip van Den Bosch^1,2, Siegfried Wassenberg³, Andrew Östör⁴, Chen Wang⁵, Vishvas Garg⁵ and Jasmina Kalabic⁶, ¹Ghent University Hospital, Ghent, Belgium, ²Rheumatology, Ghent University Hospital, Gent, Belgium, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Addenbrooke's Hospital, Cambridge, United Kingdom, ⁵AbbVie Inc., North Chicago, IL, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose : AbbVie’s Patient (pt) Support Program (PSP) is offered to pts who are prescribed adalimumab (ADA) for their Rheumatoid arthritis (RA). The purpose of…
Abstract Number: 2298 • 2017 ACR/ARHP Annual Meeting
Etanercept, Adalimumab and Methotexate Utilization By Juvenile Idopathic Arthritis Patients and the Occurrence of Uveitis
Katherine Roshak¹, Joan M Sopczynski², Ricardo Suehiro² and Lisa Marshall¹, ¹Inflammation & Immunology Global Medical Affairs, Pfizer, Collegeville, PA, ²Pfizer, Collegeville, PA
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a chronic arthritis with onset before 16 years of age, that persists for at least 6 weeks, and has…
Abstract Number: 1155 • 2017 ACR/ARHP Annual Meeting
Impact of Adalimumab on Immunosuppressant Use in Patients with Active and Inactive Non-Infectious Intermediate, Posterior, or Pan-Uveitis in the Ongoing Open Label Study: Visual-III
Sergio Schwartzman¹, Irene Van der Horst-Bruinsma², Alfredo Adan³, Hiroshi Goto⁴, Koju Kamoi⁵, Martina Kron⁶, Alexandra P. Song⁷, Kevin Douglas⁷, Sophia Pathai⁸ and C. Stephen Foster⁹, ¹Hospital for Special Surgery, New York, NY, ²Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁴Tokyo Medical University, Tokyo, Japan, ⁵Tokyo Medical and Dental University, Tokyo, Japan, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Ltd, Maidenhead, United Kingdom, ⁹Massachusetts Eye Research and Surgery foundation and Harvard Medical School, Boston, MA
Background/Purpose: The morbidity associated with the use of immunosuppressants is well described in patients (pts) with autoimmune ophthalmic disease and presents a challenge to treating…
Abstract Number: 2393 • 2017 ACR/ARHP Annual Meeting
Evaluation of Live Zoster Vaccine in a Subset of Patients with Rheumatoid Arthritis Treated with Tofacitinib with or without Methotrexate, and Adalimumab with Methotrexate: Results from a Phase 3b/4 Randomized Trial
Leonard H. Calabrese¹, Carlos Abud-Mendoza², Stephen Lindsey³, Sang Heon Lee⁴, Liza Takiya⁵, Noriko Iikuni⁶, Koshika Soma⁷, Zhen Luo⁸ and Roy Fleischmann⁹, ¹Cleveland Clinic Foundation, Cleveland, OH, ²Hospital Central, San Luis Potosí, Mexico, ³Ochsner Medical Center, Baton Rouge, LA, ⁴Konkuk University School of Medicine, Seoul, Korea, Republic of (South), ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Groton, CT, ⁸Pfizer Inc, Shanghai, China, ⁹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Patients (pts) with RA are at increased risk for herpes…
Abstract Number: 1352 • 2017 ACR/ARHP Annual Meeting
The Relevance of Elevated CRP As an Inclusion Criterion in Clinical Trials in Patients with Rheumatoid Arthritis
Craig Scoville¹, Jessica L. Suboticki², Sheng Zhong³ and Edward C. Keystone⁴, ¹Idaho Falls Arthritis Clinic, Idaho Falls, ID, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., North Chicago, IL, ⁴Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Elevated C-reactive protein (CRP) is often used as an entry criterion in clinical trials (CT) with rheumatoid arthritis (RA) patients (pts), resulting in the…
Abstract Number: 2440 • 2017 ACR/ARHP Annual Meeting
Long-Term Efficacy, Safety and Immunogenicity Results from a Randomized, Double-Blind, Phase III Confirmatory Efficacy and Safety Study Comparing GP2017, a Proposed Biosimilar, with Reference Adalimumab
Andrew Blauvelt¹, Jean-Phillipe Lacour², Joseph Fowler³, Ellen Schuck⁴, Julia Jauch-Lembach⁴, Alison Balfour⁴ and Craig Leonardi⁵, ¹Oregon Medical Research Center, Portland, OR, ²University of Nice Sophia Antipolis, Nice, France, ³Dermatology Specialists, Louisville, KY, ⁴Hexal AG, Holzkirchen, Germany, ⁵Central Dermatology, St. Louis, MO
Background/Purpose: Based on the evaluation of physicochemical, biological, preclinical, and clinical data, a biosimilar may be approved for use in the same indications for which…
Abstract Number: 1418 • 2017 ACR/ARHP Annual Meeting
The Value of Adalimumab Trough Levels and Clinical Assessments in Predicting Clinical Response in Patients with Established Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Josef S. Smolen¹, Nael Mostafa², Xin Huang², Peter Noertersheuser³, Ben Klünder³, Kun Chen², Jasmina Kalabic³, Iain Sainsbury², Ruud Oerlemans⁴, Stefan Florentinus⁴ and Gerd R. Burmester⁵, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁴AbbVie, Nederland, Hoofddorp, Netherlands, ⁵Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Free University and Humboldt University Berlin, Berlin, Germany
Background/Purpose: Low trough levels of the tumor necrosis factor inhibitor, adalimumab (ADL), and anti-ADL antibodies (AAA) were reported to be correlated with lack of response…
Abstract Number: 2442 • 2017 ACR/ARHP Annual Meeting
Biosimilar Candidate BI 695501 and Adalimumab Reference Product Have Similar Efficacy and Safety in Patients with Moderately-to-Severely Active Rheumatoid Arthritis (RA): 1-Year Results from a Phase III Study
Stanley B Cohen¹, Alberto Alonso-Ruiz², Piotr A. Klimiuk³, Eric Lee⁴, Nuala Peter⁵, Niklas Czeloth⁵ and Girish Jayadeva⁵, ¹Metroplex Clinical Research Center, Dallas, TX, ²Hospital de Cruces, Barakaldo, Spain, ³Medical University of Bialystok and Gabinet Internistyczno-Reumatologiczny, Bialystok, Poland, ⁴Inland Rheumatology, Upland, CA, ⁵Boehringer Ingelheim, Ingelheim a.R., Germany
Background/Purpose: Clinical equivalence has been shown for BI 695501 and the adalimumab reference product (RP) through similar ACR20 response at Weeks (wks) 12 and 24…
Abstract Number: 1419 • 2017 ACR/ARHP Annual Meeting
Characteristics of Patients with Early Rheumatoid Arthritis Who Have a Delayed Response to Treatment with Methotrexate in Monotherapy or in Combination with Adalimumab
Josef S. Smolen¹, Xianwei Bu², Xin Wang², Jessica L. Suboticki³ and Arthur Kavanaugh⁴, ¹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ²AbbVie Inc., North Chicago, IL, ³AbbVie Inc., Mettawa, IL, ⁴Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), treat-to-target recommendations call for adjustment of treatment if a target is not met within 3-6 months (mths)…
Abstract Number: 2443 • 2017 ACR/ARHP Annual Meeting
Randomized, Double-Blind, Single-Dose, Three-Arm Parallel Trial to Determine the Pharmacokinetics and Safety of GP2017, EU- and US-Adalimumab in Healthy Male Subjects
Julia Jauch-Lembach¹, Andrej Skerjanec¹, Halimuniyazi Haliduola¹, Nicole Hass¹, Oliver von Richter¹, Rainard Fuhr² and Thomas Koernicke², ¹Hexal AG, Holzkirchen, Germany, ²PAREXEL International GmbH, Berlin, Germany
Background/Purpose: GP2017 is a proposed adalimumab biosimilar that has been shown to be similar to reference adalimumab at an analytical and preclinical level. The aim…
Abstract Number: 1420 • 2017 ACR/ARHP Annual Meeting
The Ability of Patients with Early Rheumatoid Arthritis to Taper Low-Dose Glucocorticoids on Methotrexate Monotherapy and in Combination with Adalimumab
Josef S. Smolen¹, Prashanth Sunkureddi², Jaclyn K. Anderson³, Jenny Griffith³, Dingfeng Jiang³, Kun Chen³, Jessica L. Suboticki⁴ and Arthur Kavanaugh⁵, ¹Division of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Clear Lake Rheumatology, Nassau Bay, TX, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Inc., Mettawa, IL, ⁵Medicine, University of California, San Diego, La Jolla, CA
Background/Purpose: Low dose glucocorticoids (GCs) are recommended in combination with ≥1 synthetic DMARDs as part of the initial treatment strategy in rheumatoid arthritis (RA), with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.